Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
8.0
4.5
Journals
Cancers
Special Issues
New and Special Subtypes of Breast Cancer
share announcement

New and Special Subtypes of Breast Cancer

A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Molecular Cancer Biology".

Deadline for manuscript submissions: closed (31 December 2023) | Viewed by 1733

Special Issue Editors

Dr. Katarzyna Pogoda

E-Mail Website
Guest Editor
Breast Cancer and Reconstructive Surgery Department, Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland
Interests: breast cancer; triple-negative breast cancer; HER2-low; breast cancer in young women; BRCA mutation
Dr. Elżbieta Senkus

E-Mail Website
Guest Editor
Department of Oncology and Radiotherapy, Medical University of Gdańsk, Smoluchowskiego 17, 80-214 Gdańsk, Poland
Interests: molecular basis of breast cancer in high-risk patients; special phenotypes of breast cancer; triple-negative breast cancer

Special Issue Information

Dear Colleagues,

In the past two decades, advances in understanding breast cancer (BC) biology have translated into improvements in patients’ outcomes. New therapeutic options, such as targeted therapy and immunotherapy, have been introduced. Nowadays, we are witnessing the identification of new biological subtypes of BC, such as the HER2-low subtype. Modern antibody–drug conjugates (ADC) have been created and are tested in that condition; however, we are in the initial stages of the clinical understanding of these special subtypes. The research is also underway to assess the unique characteristics of ER-low BC. Scientific work on specific histological subtypes of breast cancer also brings new insights. The reports on the biology and management of these new, therapeutically important subtypes are highly anticipated.

In this Special Issue, “New and Special Subtypes of Breast Cancer”, we invite you to publish papers that focus on the latest achievements in the new BC subtypes including original as well as review articles. This issue aims to share the results from different sites to contribute to a broader perspective and better understanding of these new BC issues.

Research areas may include (but are not limited to) the following:

  • The pathology of new/special BC subtypes;
  • The clinical landscape of new/special BC subtypes;
  • The challenges in new/special BC subtypes.

We look forward to receiving your contributions.

Dr. Katarzyna Pogoda
Dr. Elżbieta Senkus
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • breast cancer subtype
  • HER2-low breast cancer
  • ER-low breast cancer
  • special histological breast cancer subtype
  • lobular breast cancer
  • BRCA-associated breast cancer

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (1 paper)

Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

16 pages, 2116 KiB  
Article
Clinical Characteristics and Prognosis of HER2-0 and HER2-Low-Positive Breast Cancer Patients: Real-World Data from Patients Treated with Neoadjuvant Chemotherapy
by Patrik Pöschke, Peter A. Fasching, Werner Adler, Matthias Rübner, Matthias W. Beckmann, Carolin C. Hack, Felix Heindl, Arndt Hartmann, Ramona Erber and Paul Gass
Cancers 2023, 15(19), 4678; https://doi.org/10.3390/cancers15194678 - 22 Sep 2023
Cited by 3 | Viewed by 1398
Abstract
In our study, we observed the long-term survival outcomes investigated for HER2-0 and HER2-low-positive breast cancer patients who received neoadjuvant chemotherapy. Between 1998 and 2020, 10,333 patients with primary breast cancer were treated, including 1373 patients with HER2-0 or HER2-low-positive disease with neoadjuvant [...] Read more.
In our study, we observed the long-term survival outcomes investigated for HER2-0 and HER2-low-positive breast cancer patients who received neoadjuvant chemotherapy. Between 1998 and 2020, 10,333 patients with primary breast cancer were treated, including 1373 patients with HER2-0 or HER2-low-positive disease with neoadjuvant chemotherapy. Descriptive analyses were performed, and logistic regression models and survival analyses were calculated for disease-free survival (DFS) and overall survival (OS). Among the 1373 patients, 930 (67.73%) had HER2-low-positive and 443 (32.27%) had HER2-0 tumors. Patients with HER2-0 tumors had a significantly better pathological complete response, 29.25% vs. 20.09%, and pathological complete response/in situ, 31.97% vs. 24.08%, than patients with HER2-low-positive tumors (p < 0.001; p = 0.003), regardless of the hormone receptor (HR) status. No statistically significant differences were observed for the HR-positive (p = 0.315; p = 0.43) or HR-negative subgroups (p = 0.573; p = 0.931). DFS and OS were significantly longer for HR-positive, HER2-low-positive patients (log-rank p = 0.02; p = 0.012). OS was significantly longer for HR-negative, HER2-0 patients (log-rank p = 0.032). No significant DFS differences were found for the HR-negative cohort (log-rank p = 0.232). For the overall cohort, no significant differences were noted between HER2-low-positive and HER2-0 patients, either for DFS (log-rank p = 0.220) or OS (log-rank p = 0.403). These results show different survival outcomes for HER2-0 and HER2-low-positive tumors relative to HR status. These different cohorts can be identified using standardized immunohistochemistry, even retrospectively. Full article
(This article belongs to the Special Issue New and Special Subtypes of Breast Cancer)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-1
Back to TopTop